Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX49 (DDX49) is an RNA helicase enzyme of the DEAD-box family, characterized by conserved ATPase and RNA-binding motifs that provide robust ATP-dependent RNA unwinding activity[1][3]. DDX49 is essential for various aspects of RNA metabolism, including the regulation of mRNA export from the nucleus and the control of pre-ribosomal RNA transcription and stability[1][3]. It is localized in both the nucleoplasm and nucleolus within cells and modulates global protein translation by affecting both mRNA export and ribosome biogenesis[1][3]. DDX49 promotes cell proliferation and colony-forming potential; its expression is elevated in various cancers, suggesting a pathogenic role in oncogenic transformation and tumor progression[1][2]. Dysregulation of DDX49 and related DEAD-box helicases is implicated in cancer and potentially other diseases involving aberrant RNA processing or cell cycle control[1][2]. No approved drugs or biomarker applications have been directly associated with DDX49 as of this date[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX49 (DDX49).